Sulforaphane produces antidepressant- and anxiolytic-like effects in adult mice

Behavioural Brain Research

Volumn 301, Issue , 2016, Pages 55-62

  Wu, Shuhui ^a   Gao, Qiang ^b   Zhao, Pei ^c   Gao, Yuan ^b   Xi, Yanjie ^b   Wang, Xiaoting ^b   Liang, Ying ^b   Shi, Haishui ^b   Ma, Yuxia ^b  

^a HEBEI UNIVERSITY OF CHINESE MEDICINE   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c HEBEI GENERAL HOSPITAL   (China)

Author keywords

Anxiety; Depression; Hypothalamic pituitary adrenal axis; Inflammatory response; Stress; Sulforaphane

Indexed keywords

CORTICOSTERONE; CORTICOTROPIN; INTERLEUKIN 6; SULFORAPHANE; TUMOR NECROSIS FACTOR ALPHA; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; ANXIOLYTIC AGENT; FLUOXETINE; ISOTHIOCYANIC ACID DERIVATIVE; SULFORAFAN; TUMOR NECROSIS FACTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ANXIETY; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CORTICOTROPIN BLOOD LEVEL; DEPRESSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FORCED SWIM TEST; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOMODULATION; MALE; MOUSE; NONHUMAN; NOVELTY SUPPRESSED FEEDING TEST; OPEN FIELD TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SUCROSE PREFERENCE TEST; TAIL SUSPENSION TEST; TRANQUILIZING ACTIVITY; ANIMAL; ANXIETY DISORDERS; BLOOD; CHEMISTRY; CHRONIC DISEASE; DEPRESSIVE DISORDER; DISEASE MODEL; DOSE RESPONSE; INSTITUTE FOR CANCER RESEARCH MOUSE; MENTAL STRESS; METABOLISM; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZATION;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; ANTI-ANXIETY AGENTS; ANTI-INFLAMMATORY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; CHRONIC DISEASE; CORTICOSTERONE; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOXETINE; INTERLEUKIN-6; ISOTHIOCYANATES; MALE; MICE, INBRED ICR; MOTOR ACTIVITY; RANDOM ALLOCATION; STRESS, PSYCHOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84955092945     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2015.12.030     Document Type: Article

References (52)

1. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289:3095-3105.
2. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 2006, 163:28-40.
3. Christodoulou E., Kadoglou N.P., Kostomitsopoulos N., Valsami G. Saffron: a natural product with potential pharmaceutical applications. J. Pharm. Pharmacol. 2015.
4. Tian J., Zhang F., Cheng J., Guo S., Liu P., Wang H. Antidepressant-like activity of adhyperforin, a novel constituent of Hypericum perforatum L. Sci. Rep. 2014, 4. 5632.
5. Zhu W.L., Shi H.S., Wei Y.M., Wang S.J., Sun C.Y., Ding Z.B., et al. Green tea polyphenols produce antidepressant-like effects in adult mice. Pharmacol. Res. 2012, 65:74-80.
6. Xu Y., Ku B., Tie L., Yao H., Jiang W., Ma X., et al. Curcumin reverses the effects of chronic stress on behavior, the HPA axis, BDNF expression and phosphorylation of CREB. Brain Res. 2006, 1122:56-64.
7. Miura H., Ozaki N., Sawada M., Isobe K., Ohta T., Nagatsu T. A link between stress and depression: shifts in the balance between the kynurenine and serotonin pathways of tryptophan metabolism and the etiology and pathophysiology of depression. Stress 2008, 11:198-209.
8. Claes S.J. CRH, stress, and major depression: a psychobiological interplay. Vitam. Horm. 2004, 69:117-150.
9. Pariante C.M. Depression, stress and the adrenal axis. J. Neuroendocrinol. 2003, 15:811-812.
10. Maric N.P., Adzic M. Pharmacological modulation of HPA axis in depression-new avenues for potential therapeutic benefits. Psychiat. Danub. 2013, 25:299-305.
11. Anacker C., Zunszain P.A., Carvalho L.A., Pariante C.M. The glucocorticoid receptor: pivot of depression and of antidepressant treatment?. Psychoneuroendocrinology 2011, 36:415-425.
12. Watson S., Gallagher P., Del-Estal D., Hearn A., Ferrier I.N., Young A.H. Hypothalamic-pituitary-adrenal axis function in patients with chronic depression. Psychol. Med. 2002, 32:1021-1028.
13. Hodes G.E., Kana V., Menard C., Merad M., Russo S.J. Neuroimmune mechanisms of depression. Nat. Neurosci. 2015, 18:1386-1393.
14. Loftis J.M., Huckans M., Morasco B.J. Neuroimmune mechanisms of cytokine-induced depression: current theories and novel treatment strategies. Neurobiol. Dis. 2010, 37:519-533.
15. Khandaker G.M., Pearson R.M., Zammit S., Lewis G., Jones P.B. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry 2014, 71:1121-1128.
16. O'Brien S.M., Scott L.V., Dinan T.G. Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum. psychopharmacol. 2004, 19:397-403.
17. Schiepers O.J., Wichers M.C., Maes M. Cytokines and major depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2005, 29:201-217.
18. Guerrero-Beltran C.E., Calderon-Oliver M., Pedraza-Chaverri J., Chirino Y.I. Protective effect of sulforaphane against oxidative stress: recent advances. Exp. Toxicol. Pathol. 2012, 64:503-508.
19. Zhang Y., Kensler T.W., Cho C.G., Posner G.H., Talalay P. Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:3147-3150.
20. Singh K., Connors S.L., Macklin E.A., Smith K.D., Fahey J.W., Talalay P., et al. Sulforaphane treatment of autism spectrum disorder (ASD). Proc. Natl. Acad. Sci. U. S. A. 2014, 111:15550-15555.
21. Lee S., Kim J., Seo S.G., Choi B.R., Han J.S., Lee K.W., et al. Sulforaphane alleviates scopolamine-induced memory impairment in mice. Pharmacol. Res. 2014, 85:23-32.
22. Martin-de-Saavedra M.D., Budni J., Cunha M.P., Gomez-Rangel V., Lorrio S., Del B., arrio L., et al. Nrf2 participates in depressive disorders through an anti-inflammatory mechanism. Psychoneuroendocrinology 2013, 38:2010-2022.
23. Lavich I.C., de Freitas B.S., Kist L.W., Falavigna L., Dargel V.A., Kobe L.M., et al. Sulforaphane rescues memory dysfunction and synaptic and mitochondrial alterations induced by brain iron accumulation. Neuroscience 2015, 301:542-552.
24. Gu X., Zhou Y., Wu X., Wang F., Zhang C.Y., Du C., et al. Antidepressant-like effects of auraptenol in mice. Sci. Rep. 2014, 4. 4433.
25. Zhu W.L., Shi H.S., Wei Y.M., Wang S.J., Sun C.Y., Ding Z.B., Lu L. Green tea polyphenols produce antidepressant-like effects in adult mice. Pharmacol. Res. 2012, 65:74-80.
26. Shi H.S., Zhu W.L., Liu J.F., Luo Y.X., Si J.J., Wang S.J., et al. PI3K/Akt signaling pathway in the basolateral amygdala mediates the rapid antidepressant-like effects of trefoil factor 3. Neuropsychopharmacology 2012, 37:2671-2683.
27. Szakacs J., Csabafi K., Liptak N., Szabo G. The effect of obestatin on anxiety-like behaviour in mice. Behav. Brain Res. 2015, 293:41-45.
28. Liu J., Guo M., Lu X.Y. Leptin/LepRb in the Ventral tegmental area mediates anxiety-related behaviors. Int. J. Neuropsychopharmacol. 2015.
29. Steckler T., Holsboer F., Reul J.M. Glucocorticoids and depression. Bailliere's Best Pract. Res. Clin. Endocrinol. Metab. 1999, 13:597-614.
30. Huang X., Mao Y.S., Li C., Wang H., Ji J.L. Venlafaxine inhibits apoptosis of hippocampal neurons by up-regulating brain-derived neurotrophic factor in a rat depression model. Int. J. Clin. Exp. Pathol. 2014, 7:4577-4586.
31. Lee B., Sur B., Park J., Kim S.H., Kwon S., Yeom M., et al. Chronic administration of baicalein decreases depression-like behavior induced by repeated restraint stress in rats. Korean J. Physiol. Pharmacol. 2013, 17:393-403.
32. Yang J.M., Rui B.B., Chen C., Chen H., Xu T.J., Xu W.P., et al. Acetylsalicylic acid enhances the anti-inflammatory effect of fluoxetine through inhibition of NF-kappaB, p38-MAPK and ERK1/2 activation in lipopolysaccharide-induced BV-2 microglia cells. Neuroscience 2014, 275:296-304.
33. Yin Y.Y., Ming L., Zheng L.F., Kan H.W., Li C.R., Li W.P. Bioactive compounds from Paecilomyces tenuipes regulating the function of the hypothalamo-hypophyseal system axis in chronic unpredictable stress rats. Chin. Med. J. 2007, 120:1088-1092.
34. Wang J., Chai A., Zhou Q., Lv L., Wang L., Yang Y., et al. Chronic clomipramine treatment reverses core symptom of depression in subordinate tree shrews. PloS ONE 2013, 8:e80980.
35. Sonntag A., Rothe B., Guldner J., Yassouridis A., Holsboer F., Steiger A. Trimipramine and imipramine exert different effects on the sleep EEG and on nocturnal hormone secretion during treatment of major depression. Depression 1996, 4:1-13.
36. Murray F., Smith D.W., Hutson P.H. Chronic low dose corticosterone exposure decreased hippocampal cell proliferation, volume and induced anxiety and depression like behaviours in mice. Eur. J. Pharmacol. 2008, 583:115-127.
37. Kalynchuk L.E., Gregus A., Boudreau D., Perrot-Sinal T.S. Corticosterone increases depression-like behavior, with some effects on predator odor-induced defensive behavior, in male and female rats. Behav. Neurosci. 2004, 118:1365-1377.
38. Rainer Q., Nguyen H.T., Quesseveur G., Gardier A.M., David D.J., Guiard B.P. Functional status of somatodendritic serotonin 1A autoreceptor after long-term treatment with fluoxetine in a mouse model of anxiety/depression based on repeated corticosterone administration. Mol. Pharmacol. 2012, 81:106-112.
39. Sousa N., Cerqueira J.J., Almeida O.F. Corticosteroid receptors and neuroplasticity. Brain Res. Rev. 2008, 57:561-570.
40. Gould E., Cameron H.A., Daniels D.C., Woolley C.S., McEwen B.S. Adrenal hormones suppress cell division in the adult rat dentate gyrus. J. Neurosci. 1992, 12:3642-3650.
41. Shirai Y., Fujita Y., Hashimoto R., Ohi K., Yamamori H., Yasuda Y., et al. Dietary intake of sulforaphane-rich broccoli sprout extracts during juvenile and adolescence can prevent phencyclidine-induced cognitive deficits at adulthood. PloS ONE 2015, 10:e0127244.
42. Beal M.F. Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease. Parkinsonism Rel. Disord. 2009, 15(Suppl 3):S189-S194.
43. Zhao J., Moore A.N., Redell J.B., Dash P.K. Enhancing expression of Nrf2-driven genes protects the blood brain barrier after brain injury. J. Neurosci. 2007, 27:10240-10248.
44. Zhao J., Kobori N., Aronowski J., Dash P.K. Sulforaphane reduces infarct volume following focal cerebral ischemia in rodents. Neurosci. Lett. 2006, 393:108-112.
45. Alfieri A., Srivastava S., Siow R.C., Cash D., Modo M., Duchen M.R., et al. Sulforaphane preconditioning of the Nrf2/HO-1 defense pathway protects the cerebral vasculature against blood-brain barrier disruption and neurological deficits in stroke. Free Radic. Biol. Med. 2013, 65:1012-1022.
46. Jo C., Kim S., Cho S.J., Choi K.J., Yun S.M., Koh Y.H., et al. Sulforaphane induces autophagy through ERK activation in neuronal cells. FEBS Lett. 2014, 588:3081-3088.
47. Innamorato N.G., Rojo A.I., Garcia-Yague A.J., Yamamoto M., de Ceballos M.L., Cuadrado A. The transcription factor Nrf2 is a therapeutic target against brain inflammation. J. Immunol. 2008, 181:680-689.
48. Townsend B.E., Johnson R.W. Sulforaphane induces Nrf2 target genes and attenuates inflammatory gene expression in microglia from brain of young adult and aged mice. Exp. Gerontol. 2015.
49. Jang M., Cho I.H. Sulforaphane ameliorates 3-nitropropionic acid-induced striatal toxicity by activating the Keap1-Nrf2-ARE pathway and inhibiting the MAPKs and NF-kappaB pathways. Mol. Neurobiol. 2015.
50. Mendez-David I., Tritschler L., Ali Z.E., Damiens M.H., Pallardy M., David D.J., et al. Nrf2-signaling and BDNF: a new target for the antidepressant-like activity of chronic fluoxetine treatment in a mouse model of anxiety/depression. Neurosci. Lett. 2015, 597:121-126.
51. Freitas A.E., Egea J., Buendia I., Gomez-Rangel V., Parada E., Navarro E., et al. Agmatine, by improving neuroplasticity markers and inducing Nrf2, prevents corticosterone-induced depressive-like behavior in mice. Mol. Neurobiol. 2015.
52. Townsend B.E., Johnson R.W. Sulforaphane reduces lipopolysaccharide-induced proinflammatory markers in hippocampus and liver but does not improve sickness behavior. Nutr. Neurosci. 2015.